Share on StockTwits

Several investment firms have updated their stock ratings and price targets on shares of GlaxoSmithKline plc (ADR) (NYSE: GSK) in the last week:

  • GlaxoSmithKline plc (ADR) was upgraded by analysts at Panmure Gordon from a “hold” rating to a “buy” rating.
  • GlaxoSmithKline plc (ADR) had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • GlaxoSmithKline plc (ADR) had its “underperform” rating reaffirmed by analysts at Credit Suisse.
  • GlaxoSmithKline plc (ADR) was upgraded by analysts at Argus from a “hold” rating to a “buy” rating.
  • GlaxoSmithKline plc (ADR) had its “buy” rating reaffirmed by analysts at Societe Generale.
  • GlaxoSmithKline plc (ADR) had its “buy” rating reaffirmed by analysts at Beaufort Securities.
  • GlaxoSmithKline plc (ADR) had its “buy” rating reaffirmed by analysts at Shore Capital Stockbrokers.
  • GlaxoSmithKline plc (ADR) had its “underperform” rating reaffirmed by analysts at Credit Suisse.

GlaxoSmithKline plc (NYSE:GSK) opened at 55.40 on Friday. GlaxoSmithKline plc has a 52 week low of $48.30 and a 52 week high of $56.73. The stock has a 50-day moving average of $53.79 and a 200-day moving average of $53.25. The company has a market cap of $132.7 billion and a P/E ratio of 15.59.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.